Ministry of health, labour and welfare in japan approves partial change to a new drug authorization for moderna's omicron-targeting bivalent booster covid-19 vaccine, mrna-1273.214

Cambridge, ma / accesswire / september 12, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has received approval from the ministry of health, labour and welfare (mhlw) in japan for a partial change to a new drug application for its omicron-targeting bivalent covid-19 booster, mrna-1273.214 (spikevax bivalent original/omicron ba.1). spikevax bivalent original/omicron contains mrna-1273 (spikevax) and a vaccine candidate targeting the omicron variant ba.1.
MRNA Ratings Summary
MRNA Quant Ranking